0
0
0
s2sdefault

FDA this week will release an action plan to spur development of generic versions of biologic drugs, Commissioner Scott Gottlieb said Tuesday at the POLITICO Pro Summit.

There are currently 11 so-called biosimilars, or versions of complex and high-priced biologic medicines, approved in the United States, including two that won approval this year. Several others are the object of legal battles between generic and name-brand drug manufacturers.